Stocks and InvestingStocks and Investing
Tue, November 6, 2018
Mon, November 5, 2018
Fri, November 2, 2018
Thu, November 1, 2018

Charles Duncan Maintained (ACAD) at Buy with Increased Target to $30 on, Nov 1st, 2018


Published on 2024-10-26 10:14:54 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $27 to $30 on, Nov 1st, 2018.

Charles has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matteis Paul of "Stifel" Maintained at Hold with Decreased Target to $14 on, Thursday, August 9th, 2018


These are the ratings of the 2 analyists that currently disagree with Charles


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $25 on, Wednesday, October 10th, 2018
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $27 on, Thursday, August 9th, 2018